Herpes simplex research
Research into herpes simplex is ongoing.
- 1 Vaccine Research
- 2 Herpes Simplex Virus Research
- 3 References
Various vaccine candidates have been developed, the first ones in the 1920s, but none have been successful to date.
Due to the genetic similarity of both herpes simplex virus types (HSV-1 and HSV-2), the development of a prophylactic-therapeutic vaccine which is proven effective against one type of the virus would provide fundamentals for vaccine-development for the other virus type. As of 2014, several vaccine candidates are in different stages of development as they are being tested for safety and efficacy, including at least three vaccine candidates in the US and one in Australia.
Live, Attenuated Variant of the HSV-2 Vaccine
While until the present day, diverse subunit HSV vaccines (e.g. Herpevac) have failed to protect humans from acquiring genital herpes in several clinical trials, the success of the chickenpox vaccine demonstrates that a live and appropriately attenuated α-herpesvirus may be used to safely control a human disease. This principle may be expanded to include HSV-1 or HSV-2 as portrayed in a new approach of the HSV-2 ICP0 live-attenuated HSV-2 vaccine investigated by Professor William Halford at the Southern Illinois University (SIU) School of Medicine. Although already proven as very safe and effective in studies on animals, Halford's vaccine is currently not involved in any clinical trials, mainly due to lack of funding.
Replication-defective HSV-2 Vaccine
Professor David Knipe, in his laboratory at Harvard Medical School has developed dl5-29. The dl5-29 vaccine is also known under the name ACAM-529 or HSV-529, a replication-defective vaccine that has proved successful in preventing both HSV-2 and HSV-1 infections and in combating the virus in already-infected hosts, in animal models. The HSV-529 is a leading vaccine candidate which has been investigated in numerous research publications, and is endorsed by many researchers in the field (i.a. Lynda A. Morrison and Jeffrey Cohen). It has also been shown that the vaccine induces strong HSV-2-specific antibody and T-cell responses, protects against challenge with a wild-type HSV-2 virus; greatly reduces the severity of recurrent disease; provides cross-protection against HSV-1; and renders the virus unable to revert to a virulent state or to become latent. The vaccine is now being researched and developed by Accambis (a company acquired by Sanofi Pasteur in September 2008). According to Jim Tartaglia, a company representative of Sanofi Pasteur, HSV-529 is still under development.
A phase I clinical trial is to be conducted at the NIH Clinical Center in Bethesda, MD and is supported by the NIAID's Laboratory of Infectious Diseases. As of July 2013, the NIH in collaboration with Sanofi Pasteur is holding a clinical trial of HSV-529. The trial is expected to be completed in October 2016.
Glycoprotein gD- and DNA-based vaccines
Professor Ian Frazer developed an experimental vaccine with his team at Coridon, a biotechnology company he founded in 2000. The company, now known under the name Admedus Vaccines is researching DNA technology for vaccines with prophylactic and therapeutic potential. In February 2014, it was announced that Frazer's new vaccine against genital herpes has passed human safety trials in a trial of 20 Australians. The new vaccine is designed to prevent new infections, and to cure current patients. However, further trials are needed to prove the safety and efficacy of the proposed vaccine. A phase II trial in Australia is to be initiated before the end of 2014.
A company named Genocea Biosciences has developed GEN-003, a first-in-class protein subunit T cell-enabled therapeutic vaccine, or immunotherapy, designed to reduce the duration and severity of clinical symptoms associated with moderate-to-severe HSV-2, and to control transmission of the infection. GEN-003 includes the antigens ICP4 and gD2, as well as the proprietary adjuvant Matrix-M. The first results of ongoing clinical trials have showed a strong reduction of symptoms occurrence by 72 percent and reduction by half in viral shedding. Recent reports on the vaccine's progress suggest the effects of the vaccine are fading 12 months after vaccination. The GEN-003 is currently considered to be advanced to a phase II clinical trial.
As of April 2014, Genocea is holding a clinical trial of GEN-003.
Vical has been awarded grant funding from the National Institute of Allergy and Infectious Diseases division of the NIH to develop a plasmid DNA-based vaccine to inhibit recurring lesions in patients latently infected with herpes simplex virus type 2 (HSV-2). The plasmid DNA encoding the HSV-2 antigens was formulated with Vaxfectin, Vical's proprietary cationic lipid adjuvant. The program advanced to a phase I/II trial in December 2013 on positive preclinical results, including a reproducible statistically significant reduction in viral lesion occurrence in guinea pigs latently infected with HSV-2.
As of December 2013, Vical is holding a clinical trial of their vaccine.
HerpV, a genital herpes vaccine candidate manufactured by the company Agenus has been tested in clinical trials. The first results showed some positive response to the vaccine, by eliciting a weak reduction in viral shedding by 15%. Further testing results are to show if the vaccine is a viable candidate against genital herpes.
PaxVax, a specialty vaccine company has started a cooperation with the Spector Lab at the UC San Diego Department of Cellular and Molecular Medicine, regarding the development of a genital herpes viral vector vaccine, which is currently in the preclinical stage.
The research data conducted by the company NanoBio indicates that an enhanced protection from HSV-2 is a result of mucosal immunity which can be elicited by their intranasal NE vaccine. Based on these results, additional preclinical studies are to be undertaken to optimize the dosing in guinea pigs, before the research is to be pushed further in a future clinical trial.
Biomedical Research Models, a Worcester based biopharmaceutical company has been awarded a fund for the development of a novel vaccine platform to combat mucosally transmitted pathogens such as HSV-2.
One vaccine that was under trial was Herpevac, a vaccine against HSV-2. The National Institutes of Health (NIH) in the United States conducted phase III trials of Herpevac. In 2010, it was reported that, after 8 years of study in more than 8000 women in the United States and Canada, there was no sign of positive results against the sexually transmitted disease caused by HSV-2 (and this despite earlier favorable interim reports).
A private company called BioVex began Phase I clinical trials for ImmunoVEX, another proposed vaccine, in March 2010. The Company had commenced clinical testing in the UK with its vaccine candidate for the prevention and potentially the treatment of genital herpes. The biopharmaceutical company Amgen bought BioVex and their proposed Immunovex vaccine appears to have been discontinued, furthermore it has been removed from the company's research pipeline.
A live, attenuated vaccine (which was proven very effective in clinical trials in Mexico) by the company AuRx has failed to proceed to a Phase III trial in the year 2006, due to financial reasons. The AuRx therapy was shown to be safe and decrease the occurrence of lesions by 86% after one year.  The fact that a live, attenuated vaccine induced better protection from HSV infection and symptoms is not new, because live-attenuated vaccines account for the most of the successful vaccines in the use until today. Sadly, it was not enough to motivate financial support by governmental or corporate bodies, which strongly support the more recent but less effective approaches as Glycoprotein or DNA based vaccines.
Herpes Simplex Virus Research
Researchers at the University of Florida have made a Hammerhead ribozyme that targets and cleaves the mRNA of essential genes in HSV-1. The hammerhead, which targets the mRNA of the UL20 gene, greatly reduced the level of HSV-1 ocular infection in rabbits, and reduced the viral yield in vivo. The gene-targeting approach uses a specially designed RNA enzyme to inhibit strains of the herpes simplex virus. The enzyme disables a gene responsible for producing a protein involved in the maturation and release of viral particles in an infected cell. The technique appears to be effective in experiments with mice and rabbits, but further research is required before it can be attempted in people infected with herpes.
Another possibility to eradicate the HSV-1 variant is being pursued by a team at Duke University. By figuring out how to switch all copies of the virus in the host from latency to their active stage at the same time, rather than the way the virus copies normally stagger their activity stage, leaving some dormant somewhere at all times, it is thought that immune system could kill the entire infected cell population, since they can no longer hide in the nerve cells. This is a potentially risky approach especially for patients with widespread infections as there is the possibility of significant tissue damage from the immune response. One class of drugs called antagomir could trigger reactivation. These are chemically engineered oligonucleotides or short segments of RNA, that can be made to mirror their target genetic material, namely herpes microRNAs. They could be engineered to attach and thus 'silence' the microRNA, thus rendering the virus incapable of keeping latent in their host. Professor Cullen believes a drug could be developed to block the microRNA whose job it is to suppress HSV-1 into latency.
Herpes has been used in research with HeLa cells to determine its ability to assist in the treatment of malignant tumors. A study conducted using suicide gene transfer by a cytotoxic approach examined a way to eradicate malignant tumors. Gene therapy is based on the cytotoxic genes that directly or indirectly kill tumor cells regardless of its gene expression. In this case the study uses the transfer of the Herpes simplex virus type I thymidine kinase (HSVtk) as the cytotoxic gene. Hela cells were used in these studies because they have very little ability to communicate through gap junctions. The Hela cells involved were grown in a monolayer culture and then infected with the HSV virus. The HSV mRNA was chosen because it is known to share characteristics with normal eukaryotic mRNA.
The HSVtk expression results in the phosphorylation of drug nucleoside analogues; in this case the drug ganciclovir, an anitiviral medication used to treat and prevent cytomegaloviruses, converts it into the nucleoside analogue triphosphates. Once granciclovir is phosphorylated through HSV-tk it is then incorporating DNA strands when the cancer cells are multiplying. The nucleotide from the ganciclovir is what inhibits the DNA polymerization and the replication process. This causes the cell to die via apoptosis.
Apoptosis is regulated with the help of miRNAs, which are small non-coding RNAs that negatively regulate gene expression. These miRNAs play a critical role in developing the timing, differentiation and cell death. The miRNAs effect on apoptosis has affected cancer development by the regulation of cell proliferation, as well as cell transformation. Avoidance of apoptosis is critical for the success of malignant tumors, and one way for miRNAs to possibly influence cancer development is to regulate apoptosis. In order to support this claim, Hela cells were used for the experiment discussed.
The cytotoxic drug used, ganciclovir, is capable of destroying via apoptosis transduced cells and non-transduced cells from the cellular gap junction. This technique is known as the "bystander effect,” which has suggested to scientists that the effect of some therapeutic agents may be enhanced by diffusion through gap junctional intercellular communication (GJIC) or cell coupling. GJIC is an important function in the maintaining of tissue homeostasis and it is a critical factor in balance of cells dying and surviving.
When Hela cells were transfected with the HSV-tk gene, and were then put in a culture with nontransfected cells, only the HSV-tk transfected Hela cells were killed by the granciclovir, leaving the nonviral cells unharmed. The Hela cells were transfected with the encoding for the gap junction protenin connexin 43 (Cx43) to provide a channel that permits ions and other molecules to move between neighboring cells. Both Hela cells with the HSV-tk and without the HSV-tk were destroyed. This result has led to the evidence needed to state that the bystander effect in the HSV-tk gene therapy is possibly due to the Cx-mediated GJIC.
Since the introduction of the nucleoside analogs decades ago, treatment of herpes simplex virus (HSV) infections has not seen much innovation, except for the development of their respective prodrugs. The inhibitors of the helicase–primase complex of HSV represent a very innovative approach to the treatment of herpesvirus disease.
- Chentoufi AA, Kritzer E, Yu DM, Nesburn AB, Benmohamed L (2012). "Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown". Clin. Dev. Immunol. 2012: 187585. doi:10.1155/2012/187585. PMC 3324142. PMID 22548113.
- Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B (2011). "A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine". PLoS ONE 6 (3): e17748. doi:10.1371/journal.pone.0017748. PMC 3055896. PMID 21412438.
- Halford WP, Geltz J, Gershburg E. Pan-HSV-2 IgG Antibody in Vaccinated Mice and Guinea Pigs Correlates with Protection against Herpes Simplex Virus 2. Retrieved 9 March 2014.
- Halford WP. Funding. Retrieved 3 July 2014.
- "High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo". PLoS One. Retrieved May 20, 2014.
- "Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease". ScienceDirect. Retrieved May 20, 2014.
- "Comparative Efﬁcacy and Immunogenicity of Replication-Defective, Recombinant Glycoprotein, and DNA Vaccines for Herpes Simplex Virus 2 Infections in Mice and Guinea Pigs". JOURNAL OF VIROLOGY. Retrieved May 20, 2014.
- "FOCUS | March 7, 2008 | LICENSING: Herpes Vaccine Developed at HMS Licensed for Preclinical Trials".
- Harvard Medical School:from Harvard Gazette, 15. April 2011
- "NIH launches trial of investigational genital herpes vaccine". Retrieved May 20, 2014.
- "Gardasil inventor Professor Ian Frazer's new genital herpes vaccine proves safe in passing first human trials". Retrieved 21 February 2014.
- "Admedus has further growth in sights following $8M placement". Retrieved 12 May 2014.
- "Genocea’s Therapeutic Vaccine for Herpes Simplex-2 Infection Shows Highly Significant Reductions in Clinical Symptoms at 6 Months". Business Wire 2014. Retrieved 26 March 2014.
- Sullivan, Sean M. "Development of Vaxfectin ® -formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications". Vical. Retrieved 26 March 2014.
- Herpes News: Early 2014 Roundup
- PaxVax Signs R&D Collaboration with UC San Diego to Develop a Vaccine to Prevent Herpes Simplex Virus Infections
- "NanoBio's Intranasal Vaccine Demonstrates Robust Protection Against Herpes Simplex-2 Infection". PR Newswire. Retrieved 12 May 2014.
- "BioMedical Research Models Inc awarded Grant for Mucosal HSV-2 vaccine". Vaccine Nation (Cameron Bisset). Retrieved 13 June 2014.
- "Herpevac Trial for Women". Archived from the original on 2007-10-20. Retrieved 2008-03-04.
- Jon Cohen (15 October 2010). "aPainful Failure of Promising Genital Herpes Vaccine". Science 330 (6002): 304. doi:10.1126/science.330.6002.304. PMID 20947733.
- BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine
- Amgen completes acquisition of BioVex Group
- Amgen research pipeline
- AuRx Press Release Baltimore, September 11, 2006
- Molecular Therapy (2006-05-01). "Molecular Therapy – Abstract of article: 801. RNA Gene Therapy Targeting Herpes Simplex Virus". Nature.com. Retrieved 2011-04-12.
- "University of Florida News –Potential new herpes therapy studied". News.ufl.edu. 2009-02-03. Retrieved 2011-04-12.
- Fox, Maggie (2008-07-02). "New approach offers chance to finally kill herpes". Reuters. Retrieved 2011-04-12.
- Kingsbury, Kathleen (2008-07-02). "A Cure for Cold Sores?". Time. Retrieved 2010-05-04.
- Martin, Trepel; Charlotte A. Stoneham2,5, Hariklia Eleftherohorinou3, Nicholas D. Mazarakis2, Renata Pasqualini4, Wadih Arap4, and Amin Hajitou2 (August 2009). "A Heterotypic Bystander Effect for Tumor Cell Killing after AAVPmediated Vascular-targeted Suicide Gene Transfer". Mol Cancer Ther. 8 (8): 2383–2391. doi:10.1158/1535-7163.MCT-09-0110. PMC 2871293. PMID 19671758. Retrieved 6 April 2012.
- Mesnil, M.; Piccoli, C.Tiraby, G.,Willencke K., Yamasaki,H. (March 1996). "Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins". Medical Sciences 93 (5): 1831–1835. doi:10.1073/pnas.93.5.1831. PMC 39867. PMID 8700844. Retrieved 6 April 2012.
- Stringer, J.R; LOUIS E. HOLLAND; RONALD I. SWANSTROM; 1 KENNETH PIVO; AND EDWARD K. WAGNER (March 1977). "Quantitation of Herpes Simplex Virus Type 1 RNA in Infected HeLa Cells". Journal of Virology 21 (3): 889–901. PMC 515626. PMID 191652. Retrieved 6 April 2012.
- Jovanovic, M; MO Hengartner (2006). "miRNAs and apoptosis: RNAs to die for". Nature 25 (46): 6176–6187. doi:10.1038/sj.onc.1209912. Retrieved 6 April 2012.
- Helicase–primase inhibitors as the potential next generation of highly active drugs against herpes simplex viruses